Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-22), Hansa Biopharma AB's 12-1 Month Momentum % is 37.26%.
The industry rank for Hansa Biopharma AB's 12-1 Month Momentum % or its related term are showing as below:
LTS:0RC7's 12-1 Month Momentum % is ranked better than 79.81% of 1352
companies
in the Biotechnology industry
Industry Median: -20.52
vs LTS:0RC7: 37.26
Hansa Biopharma AB (LTS:0RC7) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Hansa Biopharma AB 12-1 Month Momentum % Related Terms
LTS:0RC7 vs VRTX, REGN, MRNA: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's 12-1 Month Momentum % falls into.
Hansa Biopharma AB (LTS:0RC7) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (LTS:0RC7) has a 12-1 Month Momentum % of 37.26% as of Sep. 22, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Hansa Biopharma AB and its competitors. According to the industry distribution chart, Hansa Biopharma AB ranks #273 out of 1352 companies in the Biotechnology industry, placing it in the top 20.2%.
Is Hansa Biopharma AB's 12-1 Month Momentum % too high?
Hansa Biopharma AB's current 12-1 Month Momentum % is 37.26%. Based on the distribution chart, Hansa Biopharma AB ranks #273 out of 1352 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hansa Biopharma AB has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hansa Biopharma AB ranks #273 out of 1352 companies for 12-1 Month Momentum %. This places Hansa Biopharma AB in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current 12-1 Month Momentum % is 37.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (LTS:0RC7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr22.23, compared to a current price of kr35.97 — trading 61.8% above its estimated fair value. The current 12-1 Month Momentum % is 37.26%. Hansa Biopharma AB's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Hansa Biopharma AB (LTS:0RC7), the current 12-1 Month Momentum % is 37.26% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (LTS:0RC7) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr35.97 is trading 61.8% above its estimated GF Value™ of kr22.23.
GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.
Key valuation signals for LTS:0RC7:
12-1 Month Momentum %: 37.26%
GF Value™: kr22.23 vs. price of kr35.97 (61.8% above fair value)
No single metric tells the full story. See the LTS:0RC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
41GF Score
Get the complete analysis for LTS:0RC7
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RC7 has been successfully added to your 
